FDA in the Time of COVID-19
ABA Administrative & Regulatory Law News, Vol. 45, No. 3, 2020
3 Pages Posted: 16 Jun 2020
Date Written: May 1, 2020
Over the past century, Congress has made the Food & Drug Administration (FDA) responsible for regulating the safety and efficacy of drugs and devices being deployed in the fight against the COVID-19 pandemic. The FDA’s regulatory infrastructure was built for public health threats and to combat manufacturers' misinformation about treatments. This article spotlights the ways in which FDA has been adapting to a new challenge during the COVID-19 pandemic: combating misinformation emanating from within the executive branch.
Note: © 2020 by the American Bar Association. Reprinted with permission. All rights reserved. This information or any or portion thereof may not be copied or disseminated in any form or by any means or stored in an electronic database or retrieval system without the express written consent of the American Bar Association.
Keywords: FDA, COVID-19, coronavirus, misinformation, public health, executive, administrative law, regulation, agency, publicity, pharmaceutical
Suggested Citation: Suggested Citation